Abstract:Angelman Syndrome (AS) is characterized by severe developmental delays including marked speech impairment, movement abnormalities(ataxia, tremor), and unique behaviors such as frequent laughter and is caused by dysfunctional maternal UBE3A gene (maternal 15q11-13 deletions, maternal specific UBE3A mutation, uniparental disomy, and imprinting defect). Intractable epileptic seizures since early childhood with characteristic EEG abnormalities are present in 80-90% patients with AS. Underlying pathophysiology may involve neocortical and thalamocortical hyperexcitability secondary to severe reduction of GABAergic input, as well as dysfunctional synaptic plasticity, deficient synaptogenesis, and neuronal morphological immaturity. The onset of epilepsy is most prevalent between 1 and 3 years of age; however, approximately 25% of patients developed epilepsy before one year of age. Various types of generalized seizures are most prevalent, with most common types are myoclonic and atypical absence.More than 95% of epilepsy patients may have daily seizures at least for a limited time during early childhood, and two-third patients develop disabling seizures. Fever provoked seizures, and frequent occurrence of nonconvulsive status epilepticus are two unique features. Seizures are frequently pharmacoresistant. Considering underlying prominent GABAergic dysfunction, clinicians had used AEDs that target GABAergic signaling such as valproate, phenobarbital, and clonazepam as first-line therapies for AS. However, due to the unfavorable side effect profile of these AEDs, a recent treatment approach involves priority use of levetiracetam, clobazam, topiramate, lamotrigine, ethosuximide, VNS, and carbohydrate-restricted diets. Besides symptomatic management, there has been recent progress to find a curative treatment with the following approaches: 1. Gene/protein replacement therapy (Adeno and lentiviral vector therapy to deliver a gene or secretory protein); 2. Activation of the intact but silent paternal copy of UBE3A (antisense oligonucleotide therapy and artificial transcription factors); and 3. Downstream therapies (OV101/gaboxadol, ketone supplement, novel compounds/peptides, anti-inflammatory/regenerative therapy).

Therapies in preclinical and clinical development for Angelman syndrome

[Angelman syndrome: current approach and the future of therapies]

UBE3A reinstatement as a disease‐modifying therapy for Angelman syndrome

Neuronal UBE3A substrates hold therapeutic potential for Angelman syndrome

Emerging Gene and Small Molecule Therapies for the Neurodevelopmental Disorder Angelman Syndrome

Precision medicine in Angelman syndrome

An ASO therapy for Angelman syndrome that targets an evolutionarily conserved region at the start of the UBE3A-AS transcript

Adult Gene Therapy for Epilepsy in a Model of Angelman Syndrome: Hope or Hype?

Ube3a unsilencer for the potential treatment of Angelman syndrome

Angelman syndrome: a journey through the brain

Cas9 gene therapy for Angelman syndrome traps Ube3a-ATS long non-coding RNA

Neural hyperexcitability in Angelman syndrome: Genetic factors and pharmacologic treatment approaches

Antisense oligonucleotide treatment rescues UBE3A expression and multiple phenotypes of an Angelman syndrome mouse model

A multidisciplinary approach and consensus statement to establish standards of care for Angelman syndrome

Epilepsy in Angelman syndrome: A scoping review

Translational outcomes in a full gene deletion of ubiquitin protein ligase E3A rat model of Angelman syndrome

Angelman syndrome genotypes manifest varying degrees of clinical severity and developmental impairment

If not Angelman, what is it? A review of Angelman-like syndromes

Double-blind therapeutic trial in Angelman syndrome using betaine and folic acid.

Genotype–Phenotype Correlations in Angelman Syndrome

Genetic investigation of the ubiquitin-protein ligase E3A gene as putative target in Angelman syndrome